Regeneron Drug Cocktail Cuts Covid Hospitalization and Death 70%

Regeneron Pharmaceuticals announced Tuesday that its COVID-19 antibody treatment has proven in a clinical study to sharply reduce the risk of hospitalization or death among patients who test positive for the virus.

The company announced on its website that a trial involving more than 4,500 patients indicated that Regeneron's treatment reduced both risks by 70 percent.

The drug cocktail was also effective in shortening recovery time from two weeks to 10 days, according to the company's findings.

All of the 4,567 patients involved in Regeneron's study had at least one risk factor that put them at a heightened risk of hospitalization or death from the disease, such as obesity or heart conditions, according to the company's website.

[link to thehill.com (secure)]

Last Edited by Captain KC Jones on 03/23/2021 02:22 PM